NewsEvents

Your Yourlocation: Home > Research progress of tiotropium bromide(136310-93-5) in the treatment of chronic respiratory diseases

Tiotropium bromide(136310-93-5) is a long-term anti-cholinergic drugs, acting on the M receptor, improve the patient's lung function, anti-inflammatory, reduce the role of secretions and the gang. Chronic respiratory disease is a series of complex pathophysiological processes that are caused by a variety of inflammatory cell-mediated respiratory infections that cause limited airflow, respiratory structural remodeling, increased mucus secretion, and etc. A large number of trials have shown that patients with chronic obstructive pulmonary disease. The efficacy of tiotropium in the treatment of asthma is comparable to that of long-acting beta-agonists and may be a new method of treatment for asthma, and tiotropium bromide(136310-93-5) is also reported for rare bronchial dilatation and diffuse sexual bronchiolitis have a certain therapeutic effect. In conclusion, tiotropium has an application prospect in the treatment of respiratory diseases.

To study the therapeutic effect of inhaled tiotropium in the treatment of stable chronic obstructive pulmonary disease(COPD). Methods: Patients were randomly divided into treatment group and control group. The treatment group was inhaled tiotropium bromide(136310-93-5) powder (18 ug, 1 time /d) control group was treated theophylline, each 0.1,2 times /d, the course of treatment are 12 weeks of treatment 2 weeks, 6 weeks, 10 weeks, a total of 12 weeks of follow-up four times, before treatment, the lung function and blood gas were measured at week and 12 weeks. Results: Twenty-five patients with COPD were treated with 12 patients in the control group and 25 patients in the control group. There were no differences in sex, age, duration, smoking history, height(P> 0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05) .There was no significant difference between the two groups (P> 0.05). There were significant differences in PO2, FEV1, FEV1 /FVC (%) and FEV1 percentage of the predicted value (%) of the mean with a control group significant difference (P <0.05). Conclusion: The significantly improve pulmonary ventilation and gas exchange function of the patient, compared to the control group has significant effect, and less adverse effects than theophylline. Together with theophylline anticholinergics may produce better therapeutic effect.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved